Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gamida Cell Ltd. (Nasdaq: GMDA) has completed its public offering, closing on December 21, 2020. The offering included 9,343,750 ordinary shares at $8.00 per share, yielding gross proceeds of approximately $74.75 million before expenses. This total reflects the full exercise of underwriters' options, allowing for an additional 1,218,750 shares. Piper Sandler & Co., Evercore Group, and JMP Securities managed the offering. The securities were registered under Form F-3, declared effective on November 27, 2019.
- Raised a total of $74.75 million through the public offering.
- The offering included a successful exercise of the underwriters' options, increasing the number of shares sold.
- None.
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters’ option to purchase up to an additional 1,218,750 shares, at the public offering price of
Piper Sandler & Co., Evercore Group L.L.C. and JMP Securities LLC acted as joint book-running managers for this offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission on Form F-3 (File No. 333-234701) and declared effective on November 27, 2019. This offering was made by means of a prospectus supplement, which along with the accompanying base prospectus are part of the effective registration statement. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from: Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com; Evercore Group L.L.C., 55 East 52nd Street, New York, New York 10055, Attention: Equity Capital Markets, by telephone: (888) 474-0200, or by email at ecm.prospectus@evercore.com; or JMP Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, Attention: Prospectus Department, by calling (415) 835-8985 or by email at syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005718/en/
FAQ
What was the total amount raised in Gamida Cell's public offering on December 21, 2020?
How many shares were sold in Gamida Cell's public offering?
What was the public offering price per share for Gamida Cell?
Who were the underwriters for Gamida Cell's public offering?
What regulatory filing did Gamida Cell complete for its offering?
